ANCR Stock Overview
Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets.
Animalcare Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£2.67|
|52 Week High||UK£4.30|
|52 Week Low||UK£2.55|
|1 Month Change||-11.74%|
|3 Month Change||-20.30%|
|1 Year Change||-24.15%|
|3 Year Change||68.45%|
|5 Year Change||n/a|
|Change since IPO||-25.83%|
Recent News & Updates
Is There An Opportunity With Animalcare Group plc's (LON:ANCR) 20% Undervaluation?
Does the June share price for Animalcare Group plc ( LON:ANCR ) reflect what it's really worth? Today, we will estimate...
|ANCR||GB Pharmaceuticals||GB Market|
Return vs Industry: ANCR underperformed the UK Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: ANCR underperformed the UK Market which returned -9.5% over the past year.
|ANCR Average Weekly Movement||2.5%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||5.4%|
|10% most volatile stocks in GB Market||10.6%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: ANCR is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ANCR's weekly volatility (3%) has been stable over the past year.
About the Company
Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in the wholesale and marketing of veterinary pharmaceuticals. The company serves customers in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, other European countries, Asia, the Middle East, Africa, and internationally.
Animalcare Group Fundamentals Summary
|ANCR fundamental statistics|
Is ANCR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANCR income statement (TTM)|
|Cost of Revenue||UK£34.61m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0013|
|Net Profit Margin||-0.10%|
How did ANCR perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Is ANCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ANCR?
Other financial metrics that can be useful for relative valuation.
|What is ANCR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ANCR's PS Ratio compare to its peers?
|ANCR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
AGY Allergy Therapeutics
EAH ECO Animal Health Group
APH Alliance Pharma
STX Shield Therapeutics
ANCR Animalcare Group
Price-To-Sales vs Peers: ANCR is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (4.3x).
Price to Earnings Ratio vs Industry
How does ANCR's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?
Price-To-Sales vs Industry: ANCR is good value based on its Price-To-Sales Ratio (2.2x) compared to the UK Pharmaceuticals industry average (4.9x)
Price to Sales Ratio vs Fair Ratio
What is ANCR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.2x|
|Fair PS Ratio||3.4x|
Price-To-Sales vs Fair Ratio: ANCR is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).
Share Price vs Fair Value
What is the Fair Price of ANCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ANCR (£2.67) is trading below our estimate of fair value (£3.46)
Significantly Below Fair Value: ANCR is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANCR's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Animalcare Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ANCR's forecast earnings growth is above the savings rate (0.9%).
Earnings vs Market: Insufficient data to determine if ANCR's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if ANCR's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ANCR's revenue (3.2% per year) is forecast to grow slower than the UK market (4.1% per year).
High Growth Revenue: ANCR's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANCR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Animalcare Group performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANCR is currently unprofitable.
Growing Profit Margin: ANCR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANCR is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare ANCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.2%).
Return on Equity
High ROE: ANCR has a negative Return on Equity (-0.097%), as it is currently unprofitable.
Discover strong past performing companies
How is Animalcare Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ANCR's short term assets (£24.3M) exceed its short term liabilities (£14.5M).
Long Term Liabilities: ANCR's short term assets (£24.3M) exceed its long term liabilities (£16.8M).
Debt to Equity History and Analysis
Debt Level: ANCR's net debt to equity ratio (4.6%) is considered satisfactory.
Reducing Debt: ANCR's debt to equity ratio has reduced from 123.5% to 11.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ANCR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ANCR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 36.1% per year.
Discover healthy companies
What is Animalcare Group current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ANCR's dividend (1.8%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.91%).
High Dividend: ANCR's dividend (1.8%) is low compared to the top 25% of dividend payers in the UK market (5.28%).
Stability and Growth of Payments
Stable Dividend: ANCR has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: ANCR's dividend payments have increased, but the company has only paid a dividend for 4 years.
Earnings Payout to Shareholders
Earnings Coverage: ANCR is paying a dividend but the company is unprofitable.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (26.7%), ANCR's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jenny Winters (62 yo)
Ms. Jennifer Ann Julia Winters, also known as Jenny, BSc, serves as an Independent Non-Executive Director at EKF Diagnostics Holdings plc since February 1, 2022. She serves as Chief Executive Officer at An...
CEO Compensation Analysis
Compensation vs Market: Jenny's total compensation ($USD569.02K) is about average for companies of similar size in the UK market ($USD696.27K).
Compensation vs Earnings: Jenny's compensation has increased whilst the company is unprofitable.
Experienced Management: ANCR's management team is considered experienced (4.9 years average tenure).
Experienced Board: ANCR's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Animalcare Group plc's employee growth, exchange listings and data sources
- Name: Animalcare Group plc
- Ticker: ANCR
- Exchange: AIM
- Founded: 1972
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£160.446m
- Shares outstanding: 60.09m
- Website: https://www.animalcaregroup.com
Number of Employees
- Animalcare Group plc
- Unit 7, York Business Park
- 10 Great North Way
- North Yorkshire
- YO26 6RB
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.